Evaluation of an Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia (NOMI)
Latest Information Update: 17 Mar 2022
At a glance
- Drugs Alprostadil alfadex (Primary)
- Indications Ischaemia
- Focus Therapeutic Use
- Acronyms REPERFUSE
- 28 Feb 2022 Status changed from recruiting to completed.
- 08 Nov 2021 The primary end-point has been changed from "Change of norepinephrine dose" to "28 day mortality".
- 08 Nov 2021 Planned number of patients changed from 60 to 40.